Phlexglobal has launched a new training curriculum for CRAs, CTAs, and document managers which addresses the growing requirement for a branded mix of knowledge and skills across the roles.
The new training curriculum was established to help meet Good Clinical (Research) Practice legislation on research.
European Head of Training at Phlexglobal, Dr. Gareth Hayes, explained: "The emphasis has been on quantity and speed rather than quality and effectiveness. This has been recognized by the authorities with audit and inspection findings constantly identifying inappropriately placed personnel whose roles outstretch their capabilities."
"Transferable skills are essential behavioural components that Phlexglobal recognizes as crucial in order to satisfy the demands of the job, whether as a CRA, CTA, or document manager. They are highly marketable because they are needed for a wide variety of jobs and can be transferred from one task, job, or workplace to another."
Phlexglobal is a specialist global CRO which delivers clinical research support solutions to meet its clients’ needs through its five core services of resourcing, task force, clinical support services, eTMF, and document solution and training. It works across the pharmaceutical, biotechnology, medical device, CRO and healthcare industries.
The three core groups, focus on people skills, practical skills, and adaptability skills, and combine with role-specific GCP training (from site responsibilities to TMF architecture).
All Phlexglobal’s training can be either delivered at its headquarters in Amersham or in-house at the client’s office.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.